Antibody-drug conjugate · Kills target cells, directed at B7-H4 (VTCN1) · developed by BeOne Medicines
BG-C9074 is an antibody-drug conjugate that pairs a monoclonal antibody against B7-H4 (VTCN1), a B7 family immune modulator upregulated on tumor cells and tumor-associated macrophages, with a cytotoxic payload. After binding and internalization, the payload causes apoptosis in B7-H4-expressing cells. It is being studied in advanced solid tumors.
Summary written with AI from the sources listed at the end of this page.
Advanced Solid Tumor
Updated Oct 25, 2026. Something wrong or missing? Report it on the ONC page.
See ONC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ONC catalysts and pipeline →